Abstract The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by conducting replicating selected results from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012 were selected on the basis of citations and Altimetric scores (Errington et al
Introduction
The importance of the tumor microenvironment in cancer progression is well established. Cancerassociated fibroblasts (CAFs) are one subset of cells found in the tumor stroma that help to regulate tumor progression and metastasis through several mechanisms such as remodeling of the extracellular matrix, secretion of growth factors and chemokines, and regulation of epithelial-to-mesenchymal transition (Kalluri and Zeisberg, 2006; Cirri and Chiarugi, 2011) . Caveolin-1 (Cav1) is an essential component of caveolae and regulator of lipid raft formation that plays an important role in tumor progression (Goetz et al., 2008; Sotgia et al., 2012) . However, the precise role of Cav1 in tumor progression appears to be unclear, with studies showing both increased and decreased expression in various types of cancer (Parton and del Pozo, 2013) . One possible model is a general trend in which Cav1 appears to act as a tumor suppressor at early stages of cancer progression, but is up-regulated in several multidrug-resistant and metastatic cancer cell lines and human tumor specimens, positively correlating with tumor stage and grade in numerous cancer types (Shatz and Liscovitch, 2008) . Part of this variability could stem from Cav1 expression in stromal rather than tumor cells. For instance, loss of Cav1 function in stromal cells of various organs leads to benign stromal lesions responsible for *For correspondence: tim@cos.io abnormal growth and differentiation of the epithelium and to dramatic reductions in life span (Yang et al., 2008) . Goetz and colleagues, reported that Cav1 expression in fibroblasts remodeled the extracellular matrix to regulate cell shape and to stimulate migration and invasion of cancer cells in vitro, and promote tumor growth and metastasis in vivo in a p190RhoGAP dependent manner (Goetz et al., 2011) .
In order to specifically assess the role of Cav1 in the tumor stroma on intratumoral microenvironment remodeling and metastasis, Goetz and colleagues utilized a subcutaneous xenograft model in which primary mouse embryonic fibroblasts (pMEFs) derived from either wild type (WT) or Cav1 knock out animals (Cav1 KO) were coinjected subcutaneously with luminescent LM-4175 metastatic breast tumor cells (Minn et al., 2005) with Matrigel into nude mice (Goetz et al., 2011) . Figure 7Ca presents a graphical illustration of the experimental procedure. Primary tumor growth and metastatic tumor growth was assessed by bioluminescent imaging in vivo or ex vivo in extracted organs. Further, immunostaining of primary tumors was utilized to analyze the fiber alignment and organization of the tumor stroma in the presence of WT or Cav1 KO pMEFs, as alignment of collagen fibers in the tumor microenvironment has been shown to enhance tumor cell migration and invasion (Amatangelo et al., 2005; Provenzano et al., 2006) . It is important to note that the authors also performed shRNA knock down of p190RhoGAP in Cav1 KO pMEFs to show that the effects of Cav1 KO on metastasis could be reversed by knock down of p190RhoGAP in Cav1 KO pMEFs. This replication study will only address the effects of Cav1 expression in tumor stroma and remodeling of the tumor microenvironment matrix, and will not replicate the effects of p190RhoGAP in this model.
These experiments utilize isolated WT or Cav1 KO pMEFs, which are generated in Protocol 1. The loss of Cav1 in the Cav1 KO pMEFs (Figure 7Ca ), lead to an increase in smooth muscle actin (SMA) compared to Cav1 WT pMEFs, which is an indicator of increased activation and extra cellular matrix (ECM) remodeling capabilities of the generated pMEFs (Supplemental Figure S2A ) (Goetz et al., 2011) . These pMEFs were used in a subcutaneous tumorigenicity assay, with representative bioluminescent images of primary tumors in vivo or ex vivo in extracted organs reported in Figure 7Cc . Bioluminescence of the primary tumors or metastatic foci in each organ was quantified and shown in Figure 7Cb or Supplemental Figure S7Ca . Goetz and colleagues evaluated metastatic tumor growth where they reported an increase in metastatic foci when tumor cells were coinjected with WT pMEFs compared to tumor cells alone or tumor cells coinjected with Cav1 KO pMEFs (Goetz et al., 2011) . While not the main focus of this experiment they did not observe a difference in primary tumor growth between these conditions (Goetz et al., 2011) . This experiment is important to replicate because it tests the central tenet of the paper, namely that Cav1 expression in stromal fibroblasts contributes to increased metastasis of tumors. This experiment is replicated in Protocol 3.
Although there was no observed difference in primary tumor growth when Cav1 was absent in the tumoral stroma specifically, a decrease in primary tumor growth was observed when the whole mammary gland was deficient for Cav1 in mammary gland allografts and xenografts (Goetz et al., 2011) . In a related study, subcutaneous injection of B16 melanoma cells in Cav1 KO mice resulted in a reduced tumor growth compared to injection of tumor cells in WT mice (Chang et al., 2009) . Another study, which focused on the size of the primary tumors opposed to metastasis, reported that intradermal coinjection of nude mice with B16F10 melanoma cells and Cav1 KO neonatal dermal fibroblasts increased primary tumor growth when compared to coinjection of tumor cells with WT fibroblasts (Capozza et al., 2012) . While no known direct replications of the original study have been reported, several studies have assessed the role of stromal Cav1 expression in different types of tumors, with some studies reporting high Cav1 expression correlated with poor patient survival (Linke et al., 2010; Goetz et al., 2011; Righi et al., 2014) , and others reporting low Cav1 expression in the stroma negatively correlated with survival (Simpkins et al., 2012; Ma et al., 2013; Zhao et al., 2013; Ren et al., 2014) . Figure 7Cc and Supplemental Figure S7Cb show representative images of tumor sections immunostained for fibronectin, the CAF marker SMA, and nuclei. Goetz and colleagues showed that fibronectin fiber alignment increased in the presence of Cav1 (Goetz et al., 2011) . Supplemental Figure S7Cc shows the results of quantification of fibronectin and SMA fiber alignment as well as cell shape. Goetz and colleagues also show in Figure 7Cd that metastasis correlates with the degree of fibronectin fiber alignment in the tumor stroma. These figures are important to replicate as they show that Cav1 expression in fibroblasts contributes to remodeling of the tumor microenvironment in vivo, and that this remodeling correlates with the amount of metastasis. These experiments are replicated in Protocol 4.
Materials and methods
Protocol 1: isolation of Cav1 WT and Cav1 KO primary MEFs
This experiment describes the isolation of primary MEFs (pMEFs) that will subsequently be used in Protocols 2 and 3.
Sampling
■ Each experiment has 2 cohorts:
○ Cohort 1: Cav1-WT embryos. ○ Cohort 2: Cav1-KO embryos. ■ Experiment performed with three pregnant females in each cohort to ensure enough pMEFs are obtained. ○ Power calculations are not applicable.
Materials and reagents
Procedure Notes c This protocol contains information described in Cerezo et al. (2009 ), Razani et al. (2001 ), and Kamijo et al. (1997 . c pMEFs grown in complete DMEM: DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO 2 .
1. Sacrifice E14.5 pregnant Cav1WT (B6129SF2/J) and Cav1KO (CAV1<tm1mls>/J) mouse by cervical dislocation. 2. Dissect uterine horns and transfer to tube with ice-cold PBS to a tissue culture hood. 
Reagent

Confirmatory analysis plan
This protocol will not perform any statistical tests.
Known differences from the original study All known differences, if any, are listed in the materials and reagents section above with the originally used item listed in the comments section. The comments section also lists if the source of original item was not specified. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
All of the raw data, will be uploaded to the project page on the OSF (https://osf.io/7yqmp) and made publically available.
Protocol 2: assessment of Cav1 and SMA levels in pMEFs by western blot
This experiment assesses the protein levels of Cav1 to ensure the Cav1 KO pMEFs generated are actually knockout for Cav1. Additionally, SMA is assessed to determine if levels in Cav1 KO pMEFs are increased over Cav1 WT pMEFs, which indicate increased activation and ECM remodeling capabilities of the generated pMEFs. It is similar to the experiments reported in Figure 7Ca and Supplemental Figure S2A .
Sampling
c Each experiment has two cohorts: ○ Cohort 1: Cav1-WT pMEFs. ○ Cohort 2: Cav1-KO pMEFs. c Each clone of pMEFs will be assessed for the following markers:
○ γ-tubulin. c Experiment will be conducted once and used to assess which clones will be utilized.
○ Power calculations are not applicable.
Materials and reagents
Procedure Note c pMEFs are generated in Protocol 1. c pMEFs maintained in: DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO 2 . SDS-PAGE sample buffer and heating to 100˚C for 5 min. 4. Separate samples and molecular weight marker by SDS-PAGE gel electrophoresis in 1× trisglycine SDS buffer following replicating lab's protocol. Run at 100V through the stacking part of the gel and up to 200 V after the proteins have migrated through the resolving gel. Allow migration to continue until the blue dye front is at the bottom of the gel, but has not migrated off. a. Include Cav1 WT and Cav1 KO clones on same gel to allow comparison. 5. Transfer gel to a PVDF membrane, following replicating lab's transfer procedure. 6. After the transfer, stain the membrane with Ponceau S to visualize the transferred protein. Deliverables ■ Data to be collected: ○ Images of probed membranes (full images with ladder). ○ Raw and quantifed signal intensities normalized for γ-tubulin loading and total protein levels. ■ Sample delivered for further analysis:
○ Cav1 WT and Cav1 KO pMEFs that are included for further use (Protocol 3).
Confirmatory analysis plan
Known differences from original study
The replicating lab western blot protocol will be used. All known differences, if any, are listed in the materials and reagents section above with the originally used item listed in the comments section. The comments section also lists if the source of original item was not specified. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
Transfer quality will be assured by Ponceau staining. All of the raw data, will be uploaded to the project page on the OSF (https://osf.io/7yqmp) and made publically available. This experiment is also the quality control for the pMEFs generated in Protocol 1 that will be utilized in Protocol 3 to assess Cav1 status and ECM remodeling capabilities.
Protocol 3: subcutaneous tumorigenicity assay of tumor cells co-injected into athymic nude mice with pMEFs
This experiment tests the contribution of Cav1 expression in pMEFs on tumorigenicity and metastasis of breast cancer cells. pMEFs derived from WT or Cav1 KO animals are co-injected with LM-4175 breast cancer cells in a Matrigel plug subcutaneously in nude mice and tumor growth and metastasis are monitored by bioluminescent imaging. It is a replication of the experiment reported in Figure 7Cb and Supplemental Figure S7Ca . 
Materials and reagents
Procedure Note c pMEFs are generated in Protocol 1 with inclusion/exclusion criteria determined in Protocol 2. c pMEFs maintained in: DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37˚C in a humidified atmosphere at 5% CO 2 . c LM-4175 tumor cells express HSV-tk1-GFP-Fluc and will be sent for mycoplasma testing and STR profiling as well as screened against a Rodent Pathogen Panel. c LM-4175 maintained in: normal glucose DMEM supplemented with 10% FBS at 37˚C in a humidified atmosphere at 5% CO 2 . c Athymic nude mice should be 8-10 weeks old when they arrive and about 10-12 weeks old when injected with cells. 1. You will need 0.1 ml (2 × 10 6 cells) per injection. 2. Adjust cell mixture accordingly for needed number of injections. c. Using well-chilled tubes and pipette tips, mix each final cell suspension with an equal amount (0.1 ml) of Matrigel and store on ice. 2. Anesthetize 10-12 week old female athymic nude mice.
a. House mice under pathogen-free conditions and give autoclaved food and water ad libitum. b. Anesthetize with 100 mg/kg ketamine and 10 mg/kg xylazine. 3. Using a 25 G needle and 1 ml syringe, aspirate 0.2 ml of Matrigel/cell suspension and inject subcutaneously at the prepared site. a. During injection keep the mice warm by lying them on a warming plate designed for animal experiments. b. Stretch the abdominal cavity avoiding the formation of wrinkles. c. Inject Matrigel/cell suspension slowly by introducing the needle as parallel as possible to the skin. Ensure the Matrigel/cell suspension forms a visible bump under the skin. d. If injection enters the peritoneum, there will not be a bubble in the skin and instead of formation of one primary tumor there will be many intraperitoneal tumors. These mice should be excluded from the experiment and analysis. i. It is important not to take the needle out of the skin until the Matrigel has gelled. Gelification takes a very short time at body temperature (∼1 min). 4. Allow mice to recover and keep them warm until they wake up. 5. Maintain mice for 70 days.
a. Measure tumor size twice weekly with precision calipers. b. Initial tumor formation is defined as the time when the tumor reaches a diameter of 3 mm. The tumor should never be greater than 10% body weight or exceed 20 mm in any one dimension. If ulceration or infection at the tumor site, or interference with eating or impairment of ambulation by the tumor occurs, the animals should be euthanized. c. Additional euthanasia criteria to ensure no animal suffering (when two or more of these criteria are detected, monitor the animals for 12 hr, if the condition does not improve, euthanize): i. Rapid or progressive weight loss (more than 10% in 2 weeks x. Any condition interfering with daily activities for more than 2 hr (e.g., eating or drinking, ambulation, or elimination). xi. Excessive or prolonged hyperthermia or hypothermia. 6. At 70 days (or an earlier time point if the number of mice euthanized in step 5 compromise the ability to obtain enough mice for analysis), anesthetize each mouse and inject pairs of mice with 150 μl of 17.5 mg/ml luciferin solution intraperitoneally. a. Anesthetize with 100 mg/kg ketamine and 10 mg/kg xylazine. b. Prepare solution of luciferin according to manufacturer's instructions. c. Within each pairing of mice image, euthanize, dissect, re-image, and freeze tumors (steps 6-10) from mice from different cohorts in parallel (i.e., one from each of the three cohorts, or one each from cohort 2 and cohort 3) so variations during the procedure are equal across cohorts. 7. After 20 min post luciferin injection, place in IVIS Imaging System and take ventral views for photon flux quantification. 
Confirmatory analysis plan
This replication attempt will perform the following statistical analysis listed below: ■ Meta-analysis of effect sizes: ○ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.
Known differences from the original study
The replication attempt is not including the experimental condition of p190RhoGAP knockdown in Cav1 KO pMEFs. All known differences, if any, are listed in the materials and reagents section above with the originally used item listed in the comments section. The comments section also lists if the source of original item was not specified. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
The pMEFs used in this protocol were assessed for Cav1 status and ECM remodeling capabilities (SMA levels) in Protocol 2. The cell lines used in this experiment will undergo STR profiling to confirm their identity and will be sent for mycoplasma testing to ensure there is no contamination. Additionally, cells will be screened against a Rodent Pathogen Panel to ensure no contamination prior to injection. Mice will be injected with luciferin, imaged, euthanized, dissected, re-imaged, and tumors frozen one animal from each cohort done in parallel to have variations during the procedure equal across cohorts. All of the raw data, including the image files and quantified metastatic foci, will be uploaded to the project page on the OSF (https://osf. io/7yqmp) and made publically available.
Protocol 4: examining intratumoral fiber orientation and cell shape in tumor cells co-injected into nude mice with pMEFs
This experiment tests the effect of Cav1 expression in pMEFs on fiber orientation and cell shape within the tumor environment. Tumor sections derived from Protocol 3 are immunostained for fibronectin and smooth muscle actin, and the orientation of the fibers and cell shape are quantified. Fibronectin fiber orientation is further correlated with the amount of metastasis. It is a replication of experiments reported in Figure 7Cd and Supplemental Figure S7Cc . ii. secondary antibody only controls. 5. Wash 2 times in 1× PBS. 6. Incubate sections in secondary antibody and Hoechst dye diluted in 1× PBS supplemented with 2% BSA for 1 hr at 37˚C. a. Alexa 594 donkey-anti-rabbit; use at manufacturer's recommended dilution. b. Alexa 647 donkey-anti-mouse; use at manufacturer's recommended dilution. c. Hoechst dye; use at 1:1000 dilution. 7. Randomly image 5 independent regions per section at 20× magnification using a confocal microscope. Note: if sections are unable to be imaged due to necrosis, autofluorescence, low fibronectin deposition, or damage during the staining procedure, take images, and exclude from analysis with indicated reason. a. Total number of regions per tumor is 5 (not including control images). b. Acquire z-stack for each region with 0.5 μm-thick z-slices. c. Use a 20× objective with a minimum numerical aperture (NA) of 0.70. 8. Blindly quantify intratumoral orientation of fibronectin fibers and SMA + cells and elliptical form factor of SMA + cells. For details see Amatangelo and colleagues (Amatangelo et al., 2005) . Note: if images are unable to be evaluated due to necrosis, autofluorescence, low fibronectin deposition, or damage during the staining procedure, record as such. a. Overlay z-slices to make reconstituted views of the corresponding 3-D fibers for each region. b. Subject reconstituted 3-D projections to identical modification and digital filters as described below using MetaMorph offline 6.2r1 imaging analysis software. c. Reduce non-specific background with the Flatten Background function by selectively darkening objects with a pixel area greater than 15. d. Create a binary image by selecting a 35% threshold at the maximum internal intensity option using the internal threshold function. e. Count all fibers recognized, as well as their orientation (angle relative to x-axis) using the integrated morphometry analysis function. Use auto-threshold for light objects and measure angle of displayed objects. f. Approximate relative angles to the nearest 10th degree using the rounding function on Microsoft's Excel software and determine the mode angle for each image. Arbitrarily set the mode angle to 0˚for each image. g. Quantify the elliptical form factor (EF = length/breadth) of SMA + cells using the integrated morphometry analysis function.
Deliverables
■ Data to be collected: ○ Image stacks of fibronectin, SMA, and Hoescht-stained tumor sections for all conditions, including controls and any images taken, but unable to be analyzed (compare to Figure 7Cc and S7Cb). ○ Raw data and summary data of fibronectin fiber orientation (compare to Figure S7Cc ). ○ Raw data and summary data of elliptical form factor for SMA + cells (compare to Figure S7Cc ). ○ Raw data and summary data of SMA + cells fiber orientation (compare to Figure S7Cc ).
Confirmatory analysis plan
This replication attempt will perform the following statistical analysis listed below:
○ Wilcoxon-Mann Whitney test of percent of fibronectin fibers within ± 20˚per tumor by for the following comparisons with the Bonferroni correction: Note: in order to enable a direct comparison to how the original data was analyzed, uncorrected tests will also be performed. ○ Compute the effect sizes of each comparison, compare them against the reported effect size in the original paper and use a random effects meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.
Known differences from the original study
The replication attempt is not including the experimental condition of p190RhoGAP knockdown in Cav1 KO pMEFs. All known differences, if any, are listed in the materials and reagents section above, indicated by an asterisk, with the originally used item listed in the comments section. The comments section also lists if the source of original item was not specified. All differences have the same capabilities as the original and are not expected to alter the experimental design.
Provisions for quality control
Isotype and secondary antibody only controls will be included. If a section or image is unable to be quantified, due to necrotic damage, autofluroescence, low fibronectin deposition, or damage during the staining procedure, this data will be excluded from the analysis, similar to the original study, but recorded. The objective used to acquire the original images, that were subsequently used for the analysis was a Leica HCX PL APO CS 20×/0.70 IMM UV (communication with original authors). The replication will use a 20× objective with a minimum NA of 0.70. Images will be blindly and randomly taken and evaluated, and all of the raw data, including the control images and analysis files, will be uploaded to the project page on the OSF (https://osf.io/7yqmp) and made publically available.
Power calculations
For additional details on power calculations, please see analysis scripts and associated files on the Open Science Framework:■ https://osf.io/q3e4u/.
Protocols 1 and 2
Not applicable.
Protocol 3 Total metastatic foci per mouse
Summary of original data (provided by original authors).
Power calculations performed with G*Power software, version 3.1.7. (Faul et al., 2007) .
Test family
■ t test: means: Wilcoxon-Mann-Whitney test (two groups, one tail), alpha error = 0.0167.
Primary tumor growth
Summary of original data (provided by original authors). Analysis of original data: (Kruskal-Wallis; performed with GraphPad Prism, version 6.0).
Test family
■ F test: ANOVA: Fixed effects, omnibus, one-way, alpha error = 0.05.
Protocol 4 Percent of fibronectin fibers within ± 20S
ummary of original data (obtained from Figure S7Cc ).
Test family
■ t test: Means: Wilcoxon-Mann-Whitney test (two groups, one tail), alpha error = 0.025.
Elliptical form factor of SMA + cells
Summary of original data (obtained from Figure S7Cc ).
Power calculations performed with G*Power software, version 3.1.7. (Faul et al., 2007) . *A sensitivity calculation was performed since the original data showed a non-significant effect. This is the effect size that can be detected with the sample size reported and 80% power. †Since the non-parametric Kruskal-Wallis test will be performed for the analysis instead of an ANOVA, the sensitivity calculation was performed with a ∼15% adjustment in sample size to calculate the effect size that can be detected with 80% power. The total sample size of 49, which comes from the total metastatic foci per mouse sample size calculation, was reduced by ∼15%-41 for this calculation to estimate the detectable effect size. 
Percent of SMA + fibers within ± 20S
Test family
■ t test: means: Wilcoxon-Mann-Whitney test (two groups, one tail), alpha error = 0.025.
Correlation of percent of fibronectin fibers within ± 20˚and number of metastasis
Original data (obtained from original authors). The shared data contained 27 XY pairs with a calculated Spearman rho of 0.7488, which is missing 3 pairs included in the published analysis, with a Spearman rho of 0.81. The power calculations were performed on the shared data and Spearman rho, which will give a more conservative sample size to detect the published value.
Power calculations performed with R software, version 3.1.0 (R Development Core Team, 2014). *7 tumors will be used based on the fibronectin fiber orientation analysis making the power 94.4%. †7 tumors will be used based on the fibronectin fiber orientation analysis making the power 99.3%.
Test family
Groups
Number of simulations A priori power Total sample size % fibronectin fibers within ± 20˚and number of metastasis 10,000* 83.1% 10 *The shared data from XY pairs was randomly sampled from, with replacement, to create simulated data sets with preserved correlated structure. For a given n (the number of observations) 10,000 simulations were run and Spearman's rho was calculated for each simulated data set. The power was then calculated by counting the number of times p ≤ 0.05 and dividing by 10,000.
